T1-Weighted, Dynamic Contrast-Enhanced MR Perfusion Imaging Can Differentiate between Treatment Success and Failure in Spine Metastases Undergoing Radiation Therapy

References

1. 1.↵
   1. McLain RF

   2. Togawa D,
   3. Lewandrowski KU

   . The pathophysiology of spinal metastases. In: McLain RF. Cancer in the Spine. Humana Press; 2006:17–23
2. 2.↵
   2. Chu S,
   3. Karimi S,
   4. Peck KK, et al

   . Measurement of blood perfusion in spinal metastases with dynamic contrast-enhanced magnetic resonance imaging: evaluation of tumor response to radiation therapy. Spine (Phila Pa 1976) 2013;38:E1418–24 doi:10.1097/BRS.0b013e3182a40838 pmid:23873238

   CrossRefPubMed
3. 3.↵
   2. Norman D,
   3. Mills CM,
   4. Brant-Zawadzki M, et al

   . Magnetic resonance imaging of the spinal cord and canal: potentials and limitations. AJR Am J Roentgenol 1983;141:1147–52 doi:10.2214/ajr.141.6.1147 pmid:6606309

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Thibault I,
   3. Chang EL,
   4. Sheehan J, et al

   . Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) group. Lancet Oncol 2015;16:e595-603–603 doi:10.1016/S1470-2045(15)00166-7 pmid:26678212

   CrossRefPubMed
5. 5.↵
   2. Saha A,
   3. Peck KK,
   4. Lis E, et al

   . Magnetic resonance perfusion characteristics of hypervascular renal and hypovascular prostate spinal metastases: clinical utilities and implications. Spine (Phila Pa 1976) 2014;39:E1433–40 doi:10.1097/BRS.0000000000000570 pmid:25188594

   CrossRefPubMed
6. 6.↵
   2. Tofts PS,
   3. Brix G,
   4. Buckley DL, et al

   . Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223–32 doi:10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S pmid:10508281

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Tofts PS

   . T1-weighted DCE imaging concepts: modelling, acquisition and analysis. Magnetom Flash 2010;500:400 http://paul-tofts-phd.org.uk/DCE-MRI_siemens.pdf. Accessed July 1, 2022
8. 8.↵
   2. Meng X,
   3. Zhang Y,
   4. Liao H, et al

   . Dynamic contrast-enhanced MRI for the assessment of spinal tumor vascularity: correlation with angiography. Eur Spine J 2016;25:3952–61 doi:10.1007/s00586-016-4713-z pmid:27448809

   CrossRefPubMed
9. 9.↵
   2. Kumar KA,
   3. Peck KK,
   4. Karimi S, et al

   . A pilot study evaluating the use of dynamic contrast-enhanced perfusion MRI to predict local recurrence after radiosurgery on spinal metastases. Technol Cancer Res Treat 2017;16:857–65 doi:10.1177/1533034617705715 pmid:28449626

   CrossRefPubMed
10. 10.↵
    2. Lis E,
    3. Saha A,
    4. Peck KK, et al

    . Dynamic contrast-enhanced magnetic resonance imaging of osseous spine metastasis before and 1 hour after high-dose image-guided radiation therapy. Neurosurg Focus 2017;42:E9 doi:10.3171/2016.9.FOCUS16378 pmid:28041318

    CrossRefPubMed
11. 11.↵
    2. Chen Y,
    3. Zhang E,
    4. Wang Q, et al

    . Use of dynamic contrast-enhanced MRI for the early assessment of outcome of CyberKnife stereotactic radiosurgery for patients with spinal metastases. Clin Radiol 2021;76:864-e1 doi:10.1016/j.crad.2021.07.008 pmid:34404514

    CrossRefPubMed
12. 12.↵
    2. Hillengass J,
    3. Stieltjes B,
    4. Bäuerle T, et al

    . Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging of bone marrow in healthy individuals. Acta Radiol 2011;52:324–30 doi:10.1258/ar.2010.100366 pmid:21498370

    CrossRefPubMed
13. 13.↵
    2. Zha Y,
    3. Li M,
    4. Yang J

    . Dynamic contrast enhanced magnetic resonance imaging of diffuse spinal bone marrow infiltration in patients with hematological malignancies. Korean J Radiol 2010;11:187–94 doi:10.3348/kjr.2010.11.2.187 pmid:20191066

    CrossRefPubMed
14. 14.↵
    2. Michoux N,
    3. Simoni P,
    4. Tombal B, et al

    . Evaluation of DCE-MRI postprocessing techniques to assess metastatic bone marrow in patients with prostate cancer. Clin Imaging 2012;36:308–15 doi:10.1016/j.clinimag.2011.10.002 pmid:22726969

    CrossRefPubMed
15. 15.↵
    2. Guan Y,
    3. Peck KK,
    4. Lyo J, et al

    . T1-weighted dynamic contrast-enhanced MRI to differentiate nonneoplastic and malignant vertebral body lesions in the spine. Radiology 2020;297:382–89 doi:10.1148/radiol.2020190553 pmid:32870135

    CrossRefPubMed
16. 16.↵
    2. Verma M,
    3. Sood S,
    4. Singh B, et al

    . Dynamic contrast-enhanced magnetic resonance perfusion volumetrics can differentiate tuberculosis of the spine and vertebral malignancy. Acta Radiol 2022;63:1504–12 doi:10.1177/02841851211043838 pmid:34806421

    CrossRefPubMed
17. 17.↵
    2. Qiao P,
    3. Zhao P,
    4. Gao Y, et al

    . Differential study of DCE-MRI parameters in spinal metastatic tumors, brucellar spondylitis and spinal tuberculosis. Chin J Cancer Res 2018;30:425–31 doi:10.21147/j.issn.1000-9604.2018.04.05 pmid:30210222

    CrossRefPubMed
18. 18.↵
    2. Lang N,
    3. Su MY,
    4. Hon JY, et al

    . Differentiation of myeloma and metastatic cancer in the spine using dynamic contrast-enhanced MRI. Magn Reson Imaging 2013;31:1285–91 doi:10.1016/j.mri.2012.10.006 pmid:23290477

    CrossRefPubMed
19. 19.↵
    2. Kayhan A,
    3. Yang C,
    4. Soylu FN, et al

    . Dynamic contrast-enhanced MR imaging findings of bone metastasis in patients with prostate cancer. World J Radiol 2011;3:241–45 doi:10.4329/wjr.v3.i10.241 pmid:22229077

    CrossRefPubMed
20. 20.↵
    2. Santos P,
    3. Peck KK,
    4. Arevalo-Perez J, et al

    . T1-weighted dynamic contrast-enhanced MR perfusion imaging characterizes tumor response to radiation therapy in chordoma. AJNR Am J Neuroradiol 2017;38:2210–16 doi:10.3174/ajnr.A5383 pmid:28912284

    Abstract/FREE Full Text
21. 21.↵
    2. Arevalo-Perez J,
    3. Peck KK,
    4. Lyo JK, et al

    . Differentiating benign from malignant vertebral fractures using T1-weighted dynamic contrast-enhanced MRI. J Magn Reson Imaging 2015;42:1039–47 doi:10.1002/jmri.24863 pmid:25656545

    CrossRefPubMed
22. 22.↵
    2. Morales KA,
    3. Arevalo-Perez J,
    4. Peck KK, et al

    . Differentiating atypical hemangiomas and metastatic vertebral lesions: the role of T1-weighted dynamic contrast-enhanced MRI. AJNR Am J Neuroradiol 2018;39:968–73 doi:10.3174/ajnr.A5630 pmid:29650780

    Abstract/FREE Full Text
23. 23.↵
    2. Kerbel RS

    . Tumor angiogenesis. N Engl J Med 2008;358:2039–49 doi:10.1056/NEJMra0706596 pmid:18463380

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Carmeliet P,
    3. Jain RK

    . Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298–307 doi:10.1038/nature10144 pmid:21593862

    CrossRefPubMedWeb of Science
25. 25.↵
    2. Loi F,
    3. Córdova LA,
    4. Pajarinen J, et al

    . Inflammation, fracture and bone repair. Bone 2016;86:119–30 doi:10.1016/j.bone.2016.02.020 pmid:26946132

    CrossRefPubMed
26. 26.↵
    2. Rosenbaum SJ,
    3. Lind T,
    4. Antoch G, et al

    . False-positive FDG PET uptake: the role of PET/CT. Eur Radiol 2006;16:1054–65 doi:10.1007/s00330-005-0088-y pmid:16365730

    CrossRefPubMedWeb of Science